Literature DB >> 31794464

Congenital Muscular Dystrophy and Congenital Myopathy.

Russell J Butterfield.   

Abstract

PURPOSE OF REVIEW: Congenital muscular dystrophies and congenital myopathies are a heterogeneous group of disorders resulting in hypotonia, muscle weakness, and dystrophic or myopathic features on muscle biopsy. This article summarizes the clinical and genetic aspects of these disorders. RECENT
FINDINGS: Historically, diagnoses of congenital muscular dystrophy and congenital myopathy have been made by clinical features and histopathology; however, recent advances in genetics have changed diagnostic practice by relying more heavily on genetic findings. This article reviews the clinical and genetic features of the most common congenital muscular dystrophies including laminin subunit alpha 2 (LAMA2)-related (merosin deficient), collagen VI-related, and α-dystroglycan-related congenital muscular dystrophies and reviews the most common congenital myopathies including nemaline rod, core, and centronuclear myopathies. With the increasing accessibility of genetic testing, the number of genes found to be associated with these disorders has increased dramatically. A wide spectrum of severity and onset (from birth to adulthood) exist across all subtypes. Progression and other features are variable depending on the subtype and severity of the specific genetic mutation.
SUMMARY: Congenital muscular dystrophy and congenital myopathy are increasingly recognized disorders. A growing appreciation for the breadth of phenotypic variability and overlap between established subtypes has challenged long-standing phenotypic and histopathologic classifications of these disorders but has driven a greater understanding of pathogenesis and opened the door to the development of novel treatments.

Entities:  

Mesh:

Year:  2019        PMID: 31794464     DOI: 10.1212/CON.0000000000000792

Source DB:  PubMed          Journal:  Continuum (Minneap Minn)        ISSN: 1080-2371


  5 in total

Review 1.  FSHD Therapeutic Strategies: What Will It Take to Get to Clinic?

Authors:  Charis L Himeda; Peter L Jones
Journal:  J Pers Med       Date:  2022-05-25

Review 2.  Systemic cell therapy for muscular dystrophies : The ultimate transplantable muscle progenitor cell and current challenges for clinical efficacy.

Authors:  Hans van Bokhoven; Derick G Wansink; C Rosanne M Ausems; Baziel G M van Engelen
Journal:  Stem Cell Rev Rep       Date:  2020-12-21       Impact factor: 5.739

3.  Defining and identifying satellite cell-opathies within muscular dystrophies and myopathies.

Authors:  Massimo Ganassi; Francesco Muntoni; Peter S Zammit
Journal:  Exp Cell Res       Date:  2021-11-03       Impact factor: 3.905

4.  LAMA2 Nonsense Variant in an Italian Greyhound with Congenital Muscular Dystrophy.

Authors:  Matthias Christen; Victoria Indzhova; Ling T Guo; Vidhya Jagannathan; Tosso Leeb; G Diane Shelton; Josep Brocal
Journal:  Genes (Basel)       Date:  2021-11-19       Impact factor: 4.096

Review 5.  Diagnosis of Cardiac Abnormalities in Muscular Dystrophies.

Authors:  Elisabeta Bădilă; Iulia Ioana Lungu; Alexandru Mihai Grumezescu; Alexandru Scafa Udriște
Journal:  Medicina (Kaunas)       Date:  2021-05-12       Impact factor: 2.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.